Onconetix, a Nasdaq-listed commercial-stage biotechnology company, is dedicated to researching, developing, and commercializing innovative solutions in the field of oncology. The company's current flagship product is Entadfi®, an FDA-approved, once-daily oral therapeutic designed for treating benign prostatic hyperplasia (BPH), a prostate disorder. In addition to its existing product, Onconetix is actively expanding its portf...
Onconetix, a Nasdaq-listed commercial-stage biotechnology company, is dedicated to researching, developing, and commercializing innovative solutions in the field of oncology. The company's current flagship product is Entadfi®, an FDA-approved, once-daily oral therapeutic designed for treating benign prostatic hyperplasia (BPH), a prostate disorder. In addition to its existing product, Onconetix is actively expanding its portfolio with a focus on therapeutics, diagnostics, and services for oncology. The company is committed to advancing solutions that benefit clinicians and patients in the oncology space.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.